Lack of protective effect of chloroquine derivatives on COVID-19 disease in a Spanish sample of chronically treated patients

dc.contributor.authorLaplana Lafaja, Marina
dc.contributor.authorYuguero Torres, Oriol
dc.contributor.authorFibla Palazón, Joan
dc.date.accessioned2020-12-16T13:28:38Z
dc.date.available2020-12-16T13:28:38Z
dc.date.issued2020
dc.description.abstractBackground The search for a SARS-CoV-2 treatment has emerged as a worldwide priority. We evaluated the role of chloroquine and its derivatives in COVID-19 in Spanish individuals. Methods We performed a survey addressed to patients regularly taking chloroquine and its derivatives for the control of their autoimmune diseases. The survey was distributed with special attention to Spanish patient associations centred on autoimmune diseases and rheumatology and to the general population. A sample of untreated subjects was matched to the treated group according to sex, age range and incidence region. COVID-19 disease prevalence was compared between treated and untreated-matched control sample. Results A total of 319 surveys of patients regularly taking chloroquine and its derivatives were recovered for further analysis. The prevalence of declared COVID-19 status in the treated group was 5.3% and the mean prevalence among the untreated-matched groups was 3.4%. A community exposition to COVID-19 was associated with a greater prevalence of COVID-19 in both, treated (17.0% vs. 3.2%; p-value<0.001) and untreated groups (13.4% vs. 1.1%; p-value = 0.027). Conclusion We did not find differences of reported COVID-19 cases between treated and untreated groups, indicating a lack of protection by regular administration of chloroquine and its derivative drugs on COVID-19 infection. Of relevance, data indicates that patients that regularly take chloroquine derivatives are exposed to SARS-CoV-2 infection and must take the same protection measures as the general population.ca_ES
dc.identifier.doihttps://doi.org/10.1371/journal.pone.0243598
dc.identifier.idgrec030690
dc.identifier.issn1932-6203
dc.identifier.urihttp://hdl.handle.net/10459.1/70104
dc.language.isoengca_ES
dc.publisherPublic Library of Scienceca_ES
dc.relation.isformatofReproducció del document publicat a https://doi.org/10.1371/journal.pone.0243598ca_ES
dc.relation.ispartofPlos One, 2020, vol. 15, núm. 12, e0243598ca_ES
dc.relation.isreferencedbyhttp://hdl.handle.net/10459.1/69488ca_ES
dc.rightscc-by (c) Laplana, Marina et al., 2020ca_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccessca_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectChloroquineca_ES
dc.subjectCOVID-19 prevalenceca_ES
dc.subjectHydroxychloroquineca_ES
dc.subjectProphylaxisca_ES
dc.subjectSARS-CoV-2ca_ES
dc.titleLack of protective effect of chloroquine derivatives on COVID-19 disease in a Spanish sample of chronically treated patientsca_ES
dc.typeinfo:eu-repo/semantics/articleca_ES
dc.type.versioninfo:eu-repo/semantics/publishedVersionca_ES
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
030690.pdf
Size:
505.35 KB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: